Breaking News

AbbVie Licenses ProBioGen’s GlymaxX Technology

Will apply GlymaxX technology to boost the antibody-dependent cell-mediated cytotoxicity (ADCC).

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

ProBioGen has signed a commercial license agreement with AbbVie to apply ProBioGen’s GlymaxX technology to boost the antibody-dependent cell-mediated cytotoxicity (ADCC).   The GlymaxX technology for production of afucosylated proteins is universally applicable, simple and potent, according to the company. A single GlymaxX modified cell line is sufficient to produce both, completely fucosylated or afucosylated antibodies and those with an intermediate defined fuscosylation level. The tec...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters